Skip to main
LFCR

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical is a company that has demonstrated strong financial discipline and growth potential through its consistent execution of strategic initiatives, including winning manufacturing site transfer agreements and expanding its product offerings. The company has a solid balance sheet, with manageable leverage and a positive outlook for free cash flow generation. Despite recent market setbacks, Lifecore's operational momentum and long-term potential make it a solid investment opportunity for those with a multi-year time horizon.

Bears say

Lifecore Biomedical is showing strong potential for growth with a growing pipeline, which has been estimated to bring in over $100 million in revenue in the late-stage and commercial site transfers category. Despite these promising numbers, the impact on financial results may not be seen until 2028 or 2029. Additionally, the company's recent success in winning three commercial site transfer programs suggests that its efforts to increase visibility and drive capacity utilization are paying off, but the full benefits may not be realized until 2028.

LFCR has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Buy based on their latest research and market trends.

According to 1 analysts, LFCR has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.